Recent Updates
Recently added Catalysts
NVCR Negative Sentiment Score: 25/100

NovoCure Limited: Please contact the Portnoy Law Firm to recover your losses; August 18 2023 deadline

Key Takeaway: NovoCure Limited is facing a lawsuit filed by investors who purchased the Company’s securities during the Class Period of January 5, 2023 to June 5, 2023. The lawsuit alleges that NovoCure made false statements and omitted crucial information regarding the LUNAR study data, which may have significant implications for the Company's regulatory prospects. Interested investors are encouraged to contact the Portnoy Law Firm for potential recovery of losses and to discuss their legal rights.

Market Sentiment Analysis

CONCERNS & RISKS

  • Investors are encouraged to join a lawsuit due to alleged misleading statements by NovoCure.
  • The lawsuit claims that the Company concealed critical data about the LUNAR study.
  • Allegations suggest that the transparency of clinical efficacy data was compromised.
  • The situation raises concerns about the Company’s regulatory prospects and overall operations.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
​LOS ANGELES, Aug. 08, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises NovoCure Limited (“NovoCure” or the “Company”) (NASDAQ: NVCR) investors that a lawsuit filed on behalf of investors that purchased NovoCure securities between January 5, 2023 to June 5, inclusive (the “Class Period”)
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint asserts that the defendants engaged in false and/or deceptive statements and/or omitted important information, claiming the following:
The Company concealed the true nature of the LUNAR study data, which involved a relatively small percentage of participants who were receiving standard of care therapy.
Consequently, the reliability of the data in demonstrating clinical efficacy was significantly compromised.
The disclosure of this information had a reasonable likelihood of negatively affecting the Company's regulatory prospects and overall operations.
As a result, the Company's public statements made during the relevant times were materially false and misleading.
The allegations suggest that the defendants misrepresented the LUNAR study data and its impact, leading to potential negative consequences for the Company's regulatory prospects and operations.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What lawsuit involves NovoCure Limited?

A lawsuit was filed for investors who bought NovoCure securities from January 5 to June 5, 2023.

How can investors contact the Portnoy Law Firm?

Investors can reach attorney Lesley F. Portnoy at 844-767-8529 or lesley@portnoylaw.com.

What is the nature of the complaint against NovoCure?

The complaint claims that NovoCure concealed details about the LUNAR study's data and its implications.

What can investors expect from the Portnoy Law Firm?

The Portnoy Law Firm offers a free case evaluation and discusses options for recovering losses.

What were the consequences of NovoCure’s misleading statements?

The misleading statements may have negatively impacted the Company's regulatory prospects and operations.

Last updated: Aug 8, 2023